We are live on ! Find out more
VRNA

Verona Pharma
VRNA

Delisted

VRNA was delisted on the 6th of October, 2025.

Back to rankings

14 hedge funds and large institutions have $71.1M invested in Verona Pharma in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 14 → 14 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0.09% less ownership

Funds ownership: 6.27% → 6.18% (-0.09%)

46% less capital invested

Capital invested by funds: $132M → $71.1M (-$60.6M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
1
Increased
1
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
+$80.1K
2
OSNBOA
Old Second National Bank of Aurora
Illinois
+$24.9K

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management III
California
-$1.05M
2
PA
Perceptive Advisors
New York
-$569K
3
UBS Group
UBS Group
Switzerland
-$14K
4
TRCT
Tower Research Capital (TRC)
New York
-$3.62K
5
Morgan Stanley
Morgan Stanley
New York
-$3.36K

VRNA Hedge Fund Activity: Q2 2018 in Review

14 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2018, worth a combined $71.1M — down 46% from $132M a quarter earlier.

Fund positioning in VRNA was balanced in Q2 2018: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 4 trimmed.

The largest buyer was Deutsche Bank, adding an estimated $80.1K. The largest seller was Foresite Capital Management III, cutting an estimated $1.05M.

  • 14 institutional investors held Verona Pharma (VRNA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $71.1M of Verona Pharma stock for Q2 2018, down 46% quarter-over-quarter.
  • 1 fund opened new Verona Pharma positions in Q2 2018 and 1 closed out, a net change of 0 holders.
  • The largest Verona Pharma buyer in Q2 2018 was Deutsche Bank, an estimated $80.1K added.
  • The largest Verona Pharma seller in Q2 2018 was Foresite Capital Management III, an estimated $1.05M sold.

Based on aggregated 13F filings for Q2 2018.